Clinical trials: Human Papilloma Virus Related Carcinoma
Human Papillomavirus-Related Carcinoma
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents.
- Trial name
- NCT07104240
- Testing
- Best Practice, Educational Intervention, Health Promotion and Education
- Where
- United States
- Volunteers
- 1,836 people, healthy volunteers welcome
- Sponsor
- Emory University
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
HPV-Related Carcinoma
IBRX-042 In Participants With HPV-Associated Tumors
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV)…
- Trial name
- NCT05976828
- Testing
- IBRX-042
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- ImmunityBio, Inc.
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Carcinoma, Human Papillomavirus-Related Carcinoma
Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening
This study examines prevention and early detection of cervical cancer through self-administration screening of patients in Western Uganda.
- Trial name
- NCT04927650
- Testing
- HPV testing, Questionnaire Administration
- Where
- Uganda
- Volunteers
- 2,556 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
This phase I/II trial tests the safety, side effects, and best dose of alpelisib and whether alpelisib and carboplatin work to shrink tumors in patients with solid tumors or human papillomavirus (HPV) positive squamous cell…
- Conditions
- Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation, Human Papillomavirus-Related Carcinoma
- Trial name
- NCT05472220
- Testing
- Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate
- Sponsor
- Pamela Munster
Cervical Cancer, Anal Cancer
Detecting HPV DNA in Anal and Cervical Cancers
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer.
- Conditions
- Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma
- Trial name
- NCT04857528
- Testing
- Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Oropharynx Cancer, Stage I
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable).
- Trial name
- NCT06254911
- Testing
- Atezolizumab, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Head and Neck Carcinoma
Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer
Our institution recently began incorporating a novel "tongue-out" radiation therapy (TORT) technique for patients with head and neck tumors at particular subsites (oropharynx, larynx, hypopharynx). Protruding the tongue, i.e.
- Trial name
- NCT07227792
- Testing
- Tongue-out radiation therapy (TORT)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yvonne Mowery
HPV-Related Carcinoma, Uterine Cervical Cancer
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence.
- Conditions
- HPV-Related Carcinoma, Uterine Cervical Cancer, Anal Canal Cancer, HPV-Related Anal Squamous Cell Carcinoma
- Trial name
- ANA (NCT06640283)
- Testing
- ctDNA test, Pembrolizumab
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design.
- Conditions
- HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT03260023
- Testing
- TG4001, Avelumab
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 143 people
- Sponsor
- Transgene
Anal Cancer, HPV-Related Carcinoma
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
This study is for people who have anal cancer and have not yet had treatment. The regular treatment for people who have anal cancer is chemoradiation therapy (CRT).
- Conditions
- Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
- Trial name
- CHART-AC (NCT07425054)
- Testing
- HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jennifer Dorth
Cervical Cancer, Cervical Intraepithelial Neoplasia
Dry Run of the ScreenUrSelf Trial
The proposed study is the Dry Run preceding the ScreenUrSelf trial.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma
- Trial name
- NCT05996796
- Testing
- Colli-Pee Small Volumes, Evalyn Brush
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Human Papillomavirus-Related Cervical Carcinoma
Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort
Human papillomaviruses (HPVs) are the most common of sexually transmitted viral agents and they are associated with genital and oral diseases.
- Trial name
- PAPILLOR (NCT02774538)
- Testing
- Agreement between oral and cervical HPV infection
- Where
- 4 sites in France
- Volunteers
- 165 people
- Sponsor
- Institut de Cancérologie de Lorraine
HPV Infection, HPV-Related Cervical Carcinoma
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1.
- Trial name
- NCT04083196
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
HPV-Related Carcinoma, HPV Infection
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers.
- Trial name
- NCT06574087
- Testing
- hrHPV test and cytology
- Where
- Poland
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PCK Marine Hospital in Gdynia